Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study

por Leblond, Véronique, Aktan, Melih, Ferra Coll, Christelle M., Dartigeas, Caroline, Kisro, Jens, Montillo, Marco, Raposo, João, Merot, Jean-Louis, Robson, Susan, Gresko, Ekaterina, Bosch, Francesc, Stilgenbauer, Stephan, Foà, Robin
Publicado 2018